biomarkers
Keeping tabs on Covid-19: Vaccine results show encouraging signs in UK and China, as Israeli study offers hope to severe sufferers
July 24 by Ben WattsThe latest updates from the world of pharma as work to develop a vaccine for Covid-19 advances
The R&D Race behind Immune Checkpoint Modulators
November 14 by Chanice HenryThe cancer immunotherapy market is primed for growth, with Immune Checkpoint Inhibitors, otherwise known as Immune Checkpoint Modulators, representing one of the area’s newest and most promising treat...
The Road To ‘Personalised Medicine’ with AstraZeneca's Duncan McHale
August 17 by Pharmaceuticals & Biotechnology EditorDuncan McHale, Vice-President for Personalised Healthcare and Biomarkers, Astrazeneca, joins Helen Winsor of Pharma IQ. In this interview he discusses the importance of biomarker discov...
Troubleshooting Biomarker Development Strategies
June 09 by Gabriele DallmannIn this Pharma IQ interview Kristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation in phase I clinical developme...
An Interview with Gerd Maass, VP for R&D at Roche Pharmaceuticals: Chapter 2 - Companion Diagnostics
May 03 by Pharmaceuticals & Biotechnology EditorWhich Types of Biomarkers Truly Benefit AD?
January 25 by Andrea CharlesJohannes Streffer, Director, Experimental Medicine Europe, Janssen Research & Development, Janssen Pharmaceutica NV, speaks to Andrea Charles from Pharma IQ, about where he feels the focus...
Top Tips on Assessing Molecular Systems of Response
January 19 by Helen WinsorKarol Sikora Medical Director at CancerPartners UK, joins Helen Winsor from Pharma IQ, to discuss new trial design approaches and biomarker application methods coming on stream to drive oncology cli...
Update on Regulations Surrounding CNS in Europe: BfArM session on Optimising Clinical Development for CNS
January 11 by Pharma IQ NewsDr. Karl Broich, Vice President, BfArM, will discuss the new regulatory landscape as well as projected amendments to the current guidance documents on CNS clinical trials at Optimising Clinical...
Functional Foods: Addressing Claims & Labelling Concerns
December 24 by Pharma IQFunctional foods and beverages have represented a significant opportunity for growth within the food and drink industry over the past few years. However there are concerns regarding the claims made...
Market for CNS Biomarkers Predicted to Grow to $3.2 Billion by 2015
December 02 by Pharma IQBiomarkers are now being used by a large number of companies in the biopharmaceutical industry - and one of the key therapeutic areas where they are utilised is in CNS drug development, wher...
Challenges and Opportunities in the Use of Biomarkers in Early Phase Trials
October 07 by Pharma IQIn this interview Martin Jenkins, Senior Statistician at AstraZeneca, speaks to Andrea Charles from Pharma IQ, about exploring the potential uses of biomarkers to enhance early clinical development,...
Improving Biomarker Development Work Flow in Phase I Clinical Development
September 07 by Helen WinsorReto Ossola, Group Leader for Biomarker Research at Biognosys, joins Pharma IQ to discuss the main challenges in biomarker development and some key ways to address these. Ossola offers some best...